Nine-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes

Diabetes Care

Volumn 39, Issue 5, 2016, Pages 701-708

  Gerstein, Hertzel C ^a   Beavers, Daniel P ^b   Bertoni, Alain G ^b   Bigger, J Thomas ^c   Buse, John B ^d   Craven, Timothy E ^b   Cushman, William C ^e   Fonseca, Vivian ^f   Geller, Nancy L ^g   Giddings, Stephen J ^h   Grimm, Richard H ⁱ   Genuth, Saul ^j   Hramiak, Irene ^k   Ismail Beigi, Faramarz ^j   Jimenez, Carlos R Lopez ^c   Kirby, Ruth ^g   Probstfield, Jeffrey ^l   Riddle, Matthew C ^m   Seaquist, Elizabeth R ⁿ   Friedewald, William T ^o  

^a HAMILTON HEALTH SCIENCES   (Canada)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^g NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^h VA St Louis Healthcare System   (United States)

ⁱ UNIVERSITY OF MINNESOTA   (United States)

^j CASE WESTERN RESERVE UNIVERSITY   (United States)

^k UNIVERSITY OF WESTERN ONTARIO   (Canada)

^l UNIVERSITY OF WASHINGTON   (United States)

^m OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁿ UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^o Howard Hughes Medical Institute   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLYCEMIC CONTROL; HEALTH STATUS; HEART DEATH; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT MONITORING; RANDOMIZATION; RISK ASSESSMENT; AGED; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; FOLLOW UP; GLUCOSE BLOOD LEVEL; INCIDENCE; METABOLISM; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME;

ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

AGED; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84964758540     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-2283     Document Type: Article

References (31)

1. Gerstein HC, Werstuck GH. Dysglycaemia, vasculopenia, and the chronic consequences of diabetes. Lancet Diabetes Endocrinol 2013;1:71-78
2. Gerstein HC, Miller ME, Genuth S, et al.; ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011;364:818-828
3. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572
4. Duckworth W, Abraira C, Moritz T, et al.; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
6. Turnbull FM, Abraira C, Anderson RJ, et al.; Control Group. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:2288-2298
7. Buse JB, Bigger JT, Byington RP, et al.; ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007;99(12A):21i-33i
8. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
9. Cushman WC, Evans GW, Byington RP, et al.; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-1585
10. Ginsberg HN, Elam MB, Lovato LC, et al.; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-1574
11. Pogue J, Walter SD, Yusuf S. Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs. Clin Trials 2009;6:239-251
12. Granger CB, Vogel V, Cummings SR, et al. Do we need to adjudicate major clinical events? Clin Trials 2008;5:56-60
13. ACCORDIAN (ACCORD Trial Follow-Up Study). What is the ACCORDIAN study? [article online], 2015. Available from https://accordionstudy.org/public/dspHome.cfm. Accessed 15 September 2015
14. Punthakee Z, Miller ME, Simmons DL, et al.; ACCORD Group of Investigators. Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial. Diabetologia 2014;57:2030-2037
15. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909
16. Siraj ES, Rubin DJ, Riddle MC, et al.; ACCORD Investigators. Insulin dose and cardiovascular mortality in the ACCORD trial. Diabetes Care 2015;38:2000-2008
17. Pop-Busui R, Evans GW, Gerstein HC, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010;33:1578-1584
18. Riddle MC, Ambrosius WT, Brillon DJ, et al.; Action to Control Cardiovascular Risk in Diabetes Investigators. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. DiabetesCare 2010;33:983-990
19. Miller ME, Williamson JD, Gerstein HC, et al. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease and mortality in older versus younger adults in the ACCORD trial. Diabetes Care 2014;37:634-643
20. Calles-Escandón J, Lovato LC, Simons-Morton DG, et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010;33:721-727
21. Hempe JM, Liu S, Myers L, McCarter RJ, Buse JB, Fonseca V. The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. Diabetes Care 2015;38:1067-1074
22. Lachin JM. Point: intensive glycemic control and mortality in ACCORD - A chance finding? Diabetes Care 2010;33:2719-2721
23. Gerstein HC, Miller ME, Ismail-Beigi F, et al.; ACCORD Study Group. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet 2014;384:1936-1941
24. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
25. Hayward RA, Reaven PD, Wiitala WL, et al.; VADT Investigators. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;372:2197-2206
26. Zoungas S, Chalmers J, Neal B, et al.; ADVANCE-ON Collaborative Group. Follow-up of blood-pressure lowering and glucose control in type 2diabetes. NEngl J Med 2014;371:1392-1406
27. Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188
28. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558
29. Chew EY, Ambrosius WT, Davis MD, et al.; ACCORD Study Group; ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233-244
30. American Diabetes Association. Standards of medical care in diabetesd-2015. Diabetes Care 2015;38(Suppl. 1):S1-S93
31. Cheng AY; Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Introduction. Can J Diabetes 2013;37(Suppl. 1):S1-S3